Y-90, Capecitabine, and Atezolizumab for Oligometastatic CRC
Trial statusRecruiting
Trial phasePhase 2
Trial typeInterventional
Biological sexAll
Age18+
SponsorBrown University
About this trial
BrUOG-430 is a prospective, single-arm, phase 2 trial evaluating yttrium-90 radioembolization in combination with capecitabine and atezolizumab for the treatment of unresectable colorectal cancer liver metastases in individuals who have been treated with two or more lines of systemic therapy.
Eligibility criteria
Qualifiers
Histologically confirmed diagnosis of colorectal adenocarcinoma
Surgically unresectable, liver-isolated or liver-dominant, RECIST measurable, metastatic disease
Age ≥18 years at the time of signing informed consent
ECOG performance status 0 or 1
Disqualifiers
Prior yttrium-90 therapy
Prior external beam radiation therapy to the liver
Predicted life expectancy of less than 3 months
Known mismatch repair deficiency (dMMR), microsatellite instability (MSI-H), or high tumor mutational burden (TMB-H) defined as ≥ 10 mutations per megabase
Trial design
Treatments tested in this trial
- yttrium-90 radioembolization
Treatment groups
18 Participants
are divided into 1 treatment groupSponsors and collaborators
Source ClinicalTrials.gov